Cargando…

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

Background: The deletion of exon 19 and the Leu858Arg mutation of exon 21 are the most frequently observed mutations in the epidermal growth factor receptor (EGFR) gene, and patients with these mutations have shown significant benefits from EGFR-tyrosine kinase inhibitors (TKIs). However, there exis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Linlin, Huang, Siyuan, Qin, Liying, Yan, Ningning, Shen, Shujing, Li, Xingya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499621/ https://www.ncbi.nlm.nih.gov/pubmed/37719840 http://dx.doi.org/10.3389/fphar.2023.1257592

Ejemplares similares

A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review
por: Yang, Xian, et al.
Publicado: (2022)

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
por: Long, Xiang, et al.
Publicado: (2020)

罕见EGFR L833V/H835L复合突变的肺腺癌患者1例及文献回顾
por: MIAO, Yongen, et al.
Publicado: (2023)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
por: Qin, Bao-Dong, et al.
Publicado: (2018)

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2022)

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2023)

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
por: Zhou, Bin, et al.
Publicado: (2022)

EXM 83.5
Publicado: (1983)

CCM 83.3
Publicado: (1983)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review
por: Zhang, Qianqian, et al.
Publicado: (2022)

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
por: Qin, Zhiquan, et al.
Publicado: (2023)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
por: Lu, Shun, et al.
Publicado: (2022)

Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
por: Ao, Luyao, et al.
Publicado: (2022)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022)

Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature
por: Li, Lin
Publicado: (2022)

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
por: Zhang, Yao, et al.
Publicado: (2021)

Data acquisition system for E-835 silicon detector
por: Musico, P, et al.
Publicado: (1997)

Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review
por: Zhang, Guijuan, et al.
Publicado: (2023)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Inertial cavitation of lyophilized and rehydrated nanoparticles of poly(L-lactic acid) at 835 kHz and 1.8 MPa ultrasound
por: Hiltl, Pia, et al.
Publicado: (2019)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Jiao, Lijing, et al.
Publicado: (2019)

A Silicon Pad Detector for E-835 experiment at Fermilab
por: Buzzo, A, et al.
Publicado: (1996)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
por: Song, Xiaotong, et al.
Publicado: (2023)

833. Interaction between Aspergillus fumigatus and non-tuberculous mycobacteria
por: Namie, Hotaka, et al.
Publicado: (2023)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
por: Zeng, Yue, et al.
Publicado: (2022)

The Effect of Pungent and Tingling Compounds from Piper nigrum L. on Background K(+) Currents
por: Beltrán, Leopoldo R., et al.
Publicado: (2017)

TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma
por: Zhong, Anyuan, et al.
Publicado: (2021)

Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR(L858R/T790M)
por: Wang, Yuwei, et al.
Publicado: (2018)

Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim
por: Zheng, Jianxiao, et al.
Publicado: (2021)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

Inhibitory Effects of Twenty-Nine Compounds From Potentilla longifolia on Lipid Accumulation and Their Mechanisms in 3T3-L1 Cells
por: Ma, Qianqian, et al.
Publicado: (2020)

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells
por: Chen, ZiSheng, et al.
Publicado: (2019)

Phytochemical Characterization of Mentha spicata L. Under Differential Dried-Conditions and Associated Nephrotoxicity Screening of Main Compound With Organ-on-a-Chip
por: Li, Xian, et al.
Publicado: (2018)

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients
por: PASSAMANO, LUIGIA, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_v2bd004ttjiq1mf4n6gdk7fe4a